Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 4Completed 2Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 5004Neoplasms 4197Prostatic Neoplasms 2428Carcinoma, Non-Small-Cell Lung 2265Colorectal Neoplasms 2053Lung Neoplasms 1705Multiple Myeloma 1459Lymphoma 1405Leukemia, Myeloid, Acute 1382Neoplasm Metastasis 1374Melanoma 1270Pancreatic Neoplasms 1200Leukemia 1196Ovarian Neoplasms 1192Lymphoma, Non-Hodgkin 1132Precursor Cell Lymphoblastic Leukemia-Lymphoma 1091Head and Neck Neoplasms 1056Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 897Colonic Neoplasms 895Brain Neoplasms 876Stomach Neoplasms 857Recurrence 853Carcinoma, Hepatocellular 846Glioblastoma 841Lymphoma, Large B-Cell, Diffuse 771Rectal Neoplasms 759Uterine Cervical Neoplasms 728Carcinoma, Renal Cell 705Hodgkin Disease 698

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × Perivascular Epithelioid Cell Neoplasms × Clear all
NCT03190174 2025-02-17

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Sarcoma Oncology Research Center, LLC

Phase 1/2 Completed
34 enrolled 14 charts
DermatologicGastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Chordoma, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Sarcoma, Ewing, Colorectal Neoplasms, Desmoid Tumors, Perivascular Epithelioid Cell Neoplasms

NCT02494570 2023-04-07

AMPECT

Aadi Bioscience, Inc.

Phase 2 Completed
34 enrolled 15 charts 1 FDA

Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡